Commentary Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/AIDS.3.019
Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study
Max Lataillade1,*, Peter Ackerman1, Till Schoofs2, Andrew Clark3, Michael Kozal4
- 1ViiV Healthcare, Branford, CT, USA
- 2ViiV Healthcare, Brussels, Belgium
- 3ViiV Healthcare, Brentford, UK
- 4Yale University School of Medicine, New Haven, CT, USA
Corresponding Author
Max Lataillade, max.x.lataillade@viivhealthcare.com
Received Date: March 23, 2021
Accepted Date: June 21, 2021
Citation:
Lataillade M, Ackerman P, Schoofs T, Clark A, Kozal M. Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study. J AIDS HIV Treat. 2021; 3(2): 31-36.
Copyright: © 2021 Lataillade M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.